The Reason Why Samchundang Pharmaceutical's Stock Plummeted 25% Despite Securing a $100 Million Contract for GLP-1 Generics in the U.S.

\n

Samchundang Pharm Ventures into the U.S. GLP-1 Generic Market: How Oral Semaglutide Could Revolutionize the Game

GLP-1 has emerged as a key keyword in the global diabetes and obesity treatment market. Among them, South Korean pharmaceutical company Samchundang Pharm has pulled out the card to enter the U.S. market by expanding the trend—previously dominated by injectable drugs—into the realm of oral semaglutide (Rybelsus, Wegovy). So what kind of change could the “challenge by a domestic company in the U.S. oral GLP-1 generic market” bring to the industry?

The Core of Samchundang Pharm’s U.S. Deal: Betting on Oral Semaglutide Generics

Samchundang Pharm has secured a foothold for commercialization in the U.S. by signing an exclusive license agreement with its American partner for oral semaglutide generics. The disclosed terms convey a clear message:

• Milestone payments totaling $100 million
• Targets: Rybelsus generics (1.5–14 mg), Wegovy generics (1.5–25 mg)
• Profit sharing for 10 years post-launch: 90% to Samchundang, 10% to partner

This structure especially suggests a "revenue leverage on success" far beyond a simple technology transfer, meaning that once the high hurdles of approval and launch are cleared, Samchundang Pharm’s contribution to earnings could significantly soar.

The Distinguishing Factor: ‘S-PASS’—Absorption Enhancement Technology Built on Patent Avoidance Logic

The trickiest point in oral semaglutide lies in “how to enable absorption.” Samchundang Pharm claims its unique platform, ‘S-PASS,’ which does not use SNAC, helps bypass the core barriers of the original drug.

Why is this crucial? Simply put, oral formulations have high technical barriers, with patents, formulations, and absorption enhancement methods tightly interwoven—making it impossible for generics to enter the market by merely matching the ingredient. Ultimately, Samchundang Pharm’s challenge will be judged on technical credibility (patent circumvention potential) and regulatory plus clinical data (approval feasibility).

Expectations and Caveats: Risk Checkpoints Samchundang Must Overcome

This deal isn’t just bathed in rosy prospects. The agreement includes pragmatic safety measures such as clauses allowing modification or termination if milestones aren’t met, and termination rights if the partner deems commercialization unfeasible. More fundamentally, several variables remain unresolved:

• Clinical and regulatory success: Oral GLP-1 is a data-driven battlefield
• Commercialization speed and competitive landscape: The U.S. market offers huge rewards and high failure costs alike
• Market trust issues: The immediate stock plunge after the announcement may indicate a market reassessing uncertainties rather than resolving them

Ultimately, Samchundang Pharm’s U.S. entry is not a finish line at “signing the contract” but a three-stage test of clinical trials, regulatory approval, and product launch that will determine its true evaluation.

Conclusion: What Samchundang Pharm’s U.S. GLP-1 Generic Challenge Signals

Samchundang Pharm’s move is a major signal as it represents a domestic pharma testing its mettle in the global oral GLP-1 generic market. Success could ignite a pricing and accessibility battle amidst the mainstreaming of oral GLP-1s, while failure might reaffirm how challenging it is to commercialize oral drug platforms. For observers, one question shines above all: “When will Samchundang Pharm’s S-PASS be proven by data?” That moment will likely be the market’s ultimate verdict.

The Hidden Truth Behind Samchundang Pharmaceutical’s $100 Million Deal: Structure Matters More Than Numbers

An exclusive license agreement with a confidential partner, coupled with a total $100 million milestone, may look like a “major contract” on the surface, but the real story lies not in the amount itself, but in the payment terms and profit-sharing structure that shape its practical significance. Breaking down what Samchundang Pharmaceutical has gained—and what it has yet to secure—reveals a much clearer picture.

The $100 Million Milestone Is Not “Guaranteed Revenue,” but “Conditional Compensation”

Milestones generally represent payments made at each development stage (clinical trials, approval, launch, reaching sales targets, etc.). In other words, the “$100 million total” is near the maximum potential, and actual cash inflow hinges on several variables:

• Success of clinical trials and approval processes: If these are not passed, the next stage payments vanish.
• Progress toward commercialization: The clause allowing the partner to terminate the contract with 90 days’ notice if commercialization is deemed unfeasible increases uncertainty about receiving milestones.
• Timing of the product launch: For generics, “when the product hits the market” can decide success or failure, so delays mean delayed payments.

In summary, if the market initially priced in the $100 million as “immediate cash,” post-announcement reassessment tends to highlight that it is in fact conditional.

The 90:10 Profit Split Looks Generous but Is Really About “Role Allocation”

A standout element in this deal is the distribution of net profits after launch over 10 years at a 9:1 ratio (Samchundang 90%, partner 10%). Given that typical license agreements often involve royalties in the low single digits to low teens percentage-wise, this ratio appears heavily favorable to Samchundang at first glance.

However, the real crux is not “receiving 90%,” but rather:

• What costs and responsibilities Samchundang assumes
• What commercialization functions the partner performs (distribution, insurance, sales, regulatory affairs, etc.)
• How net profit is calculated and what expenses are deducted before splitting

Because net profit-sharing agreements are structurally more complex than revenue-sharing, the interpretive angle can substantially affect perceived profitability.

The Value of “Exclusivity”: Securing Market Entry but Not “Market Certainty”

The fact that this is an exclusive license agreement with a U.S. partner carries significant weight. Exclusivity generally provides reassurance that no competing candidates are attached with the partner, but conversely, it means the success or failure depends tightly on the execution capabilities of that single partner.

Furthermore, the contract includes protections allowing modification or termination if sales fall below 50% of expectations for two consecutive years. This is Samchundang’s way of managing risk, but from a market perspective, it sends a signal that “expected sales themselves are contingent” and not guaranteed.

Conclusion: This Contract Is Not a “Guaranteed Jackpot” but a “Ticket to a Big Game”

Samchundang’s $100 million deal undoubtedly formalizes its entry into the U.S. market. Yet from an investment viewpoint, the essential questions narrow down to:

• How much, and when, will milestones actually convert into cash?
• How much of that 90% net profit translates into real earnings after accounting and cost structures?
• Who bears what level of clinical, approval, and commercialization risk?

Ultimately, this agreement is a battle to understand “structure” rather than “numbers.” Only by scrutinizing the terms and conditions beyond headline figures can the true value of this deal be fully appreciated.

Samchundang Pharmaceutical’s Proprietary Technology S-PASS: The Key to Surpassing Patent Barriers

The essence of oral drug absorption enhancement lies not in the “ingredient itself” but in how stably it can be absorbed by the body. So, how has Samchundang Pharmaceutical’s S-PASS platform managed to evade existing patents while carving out competitiveness?

Absorption Enhancement Designed Without SNAC: The Starting Point of Patent Avoidance

Samchundang Pharmaceutical reveals that it took a different route from the well-known SNAC (sodium N-8-[2-hydroxybenzoyl] amino carboxylate) based approach used by the original oral semaglutide (Rybelsus). In other words, by proposing an absorption enhancement platform (S-PASS) that does not use SNAC, they aim to reduce the influence of formulation and absorption technology patents—one of the toughest hurdles in generic drug development.

Formulation Competition Focused on “Equivalent Performance” Rather Than “Identical Effect”

Oral formulations are not simply about replicating the active ingredient. Peptide drugs, in particular, are easily degraded in the gastrointestinal environment, making absorption efficiency and reproducibility crucial battlegrounds. This is the point where S-PASS becomes Samchundang’s ace.

• Differentiation Point: Designed to achieve oral absorption performance without relying on the same absorption enhancers as the original
• Business Implication: If successful, this technology can establish a formulation technology-based entry barrier, moving beyond mere cost competition

The Greater the Value of the Technology, the Higher the Hurdles for Validation

However, “patent avoidance potential” does not directly guarantee “commercial success.” For S-PASS to be competitive, it must pass standards such as efficacy, equivalence, and manufacturing reproducibility during clinical and regulatory processes. In other words, S-PASS is the key Samchundang has drawn to overcome patent walls—but whether this key actually opens the door depends on the next stage, to be proven by data.

Background Behind SamChundang Pharm’s Stock Plunge and Investor Anxiety

While the contract announcement seemed like good news, the market responded with a dramatic stock plunge of over 25%. On top of this, the CEO’s share sale disclosure further intensified investor unease. This harsh reaction isn’t about the deal being “bad,” but rather reflects a burst of structural factors that often surface simultaneously in stocks with built-up expectations.

‘Material Fading’ and Profit-Taking at the Peak of Expectations

The anticipated U.S. expansion of SamChundang Pharm was already largely priced into the stock. When the contract was actually announced, the market often interprets it not as a fresh catalyst but as “the awaited event becoming reality,” leading to material fading (selling on the news).
This environment encourages rapid profit-taking, triggering sharp declines.

Uncertainties Loom Larger than the ‘Contract Size’: Clinical, Regulatory, and Commercial Risks

Milestone payments totaling $100 million and a 9:1 profit split over 10 years post-launch certainly sound attractive. Yet investors scrutinize the conditions needed to realize those figures even more critically than the numbers themselves.

• Clinical and regulatory approval risks: Even for generics, oral formulations and absorption enhancements present hurdles involving regulations, trials, and data requirements that are not trivial.
• Sustainability of commercialization: Clauses allowing the partner to terminate if commercialization is difficult create an impression that the deal is vulnerable at any time.
• Contract change/termination clauses for underperformance: The possibility of renegotiation or termination if sales fall below 50% of estimates for two consecutive years detracts from the certainty of long-term cash flows from an investor’s viewpoint.

In other words, once the positive news is read as a conditional, future value rather than "confirmed revenue," the market applies a higher discount rate and re-prices the stock accordingly.

CEO’s Share Sale Disclosure Amplifies ‘Trust’ Risk

When the CEO’s substantial share sale announcement coincides with heightened stock sensitivity, the market tends to first react with psychological suspicion, regardless of the facts.
Questions arise: “Why is the person with the most information selling?” This doubt can temporarily undermine the credibility of the investment story and accelerate selling pressure.

Conclusion: Even a Good Deal’s Impact on Stock Depends on ‘Timing’ and ‘Certainty’

To sum up, the plunge in SamChundang Pharm’s stock price reflects more than a simple valuation of the contract itself—it is the result of a chain reaction: accumulated expectations → profit-taking right after the event → reassessment of conditional performance structure → trust shaken by share sale issue.
For investors, this means that the key focus has shifted away from “contract signing” toward the concreteness of clinical and approval processes, the commercialization roadmap, and partnership durability.

The Future and Challenges of Samchundang Pharmaceutical’s Entry into the Global Generic Market

Following contracts in 11 European countries and a partnership in the United States, Samchundang Pharmaceutical’s expansion strategy clearly paints a grand “picture.” However, the company’s next phase hinges not on securing contracts but on actually overcoming the highest hurdles: clinical trials and regulatory approval. The reason this journey demands close attention is not just the phrase “overseas expansion” but because multiple variables that determine the likelihood of successful commercialization are simultaneously in motion.

The Significance of Connecting Europe and the U.S.: Wider Markets, Tougher Validation

• Diversified market portfolio: Targeting both Europe and the U.S. reduces regional risks, allowing momentum to be sustained in one territory even if delays arise in another.
• Conversely, a heavier burden of proof: The U.S., with its stringent regulations and fierce competition, demands even more rigorous differentiation in technology and formulation, as well as completeness in data. The true challenge lies not in ‘entry’ but in ‘passing’ approval.

Key Challenge 1) Clinical and Regulatory Success: Turning Contract Numbers into Reality

Even though these contracts outline milestones and revenue-sharing frameworks, clinical and regulatory triumph remains a prerequisite. The toughest aspect in oral formulations ultimately centers on absorption, reproducibility, and stable manufacturing (scale-up), where even minor variables can disrupt the entire timeline.

Key Challenge 2) Proving Technology Differentiation in a ‘Regulator-Friendly’ Way: The Task for S-PASS

Samchundang emphasizes its strength in the S-PASS platform that does not use SNAC. However, the market demands not just explanations but data that convinces regulators.

• Consistency in absorption-enhancing mechanisms
• Management of batch-to-batch variability
• Long-term safety and quality control systems
  Such stringent criteria must be thoroughly met to increase commercialization potential.

Key Challenge 3) Partnership Management Risk: What Termination and Modification Clauses Reveal

The contracts include realistic safeguards such as the option to alter or terminate if sales fall below 50% of expectations for two consecutive years, and partner termination with 90 days’ notice if commercialization is unfeasible. This signals that future success will depend not only on “technology” but also on execution capabilities like market penetration speed, supply reliability, and pricing/distribution strategies.

What to Watch Moving Forward: It’s Not ‘Global Entry’ but ‘Global Commercialization’

Ultimately, Samchundang’s real question converges on one point: Will the expansion strategy spanning Europe and the U.S. translate into actual sales and profits?
Going forward, the market’s judgment will likely rely more on ▲specific milestones in clinical progress ▲clarity of regulatory strategy ▲trustworthiness of manufacturing and quality systems ▲execution roadmaps with partners rather than simply contract announcements.